Literature DB >> 17894029

Pulmonary blood volume in rheumatic heart disease and its alteration by isoproterenol.

C J McGaff, G C Roveti, E Glassman, W R Milnor.   

Abstract

Pulmonary blood volume was measured in five hemodynamically normal subjects and 37 patients with heart disease. Mean pulmonary blood volume in 25 of these patients with moderate to severe mitral stenosis, alone or complicated by other valvular lesions, was 359 ml. per M.2 (SE = +/-24 ml. per M.2), which was significantly higher than the average value of 230 ml. per M.2 (SE = +/-14 ml. per M.2) in the five normal subjects (p < 0.025). Multiple correlation of pulmonary blood volume with left atrial mean pressure, pulmonary vascular resistance, and stroke volume showed that each of these factors was significantly related to pulmonary blood volume, independently of the others. Increased left atrial pressure or stroke volume was associated with relatively high, and increased pulmonary vascular resistance with relatively low pulmonary blood volume. In seven subjects 10 to 20 mg. of isoproterenol administered sublingually led to a marked increase in pulmonary blood volume and a small decrease in pulmonary vascular resistance. The average increase in pulmonary blood volume was 78 ml. per M.2, or 35 per cent of the control value (SE = +/-15 ml. per M.2), while the average drop in pulmonary vascular resistance was 1.3 R.U.M.2 (SE = +/-0.5 R.U.M.2). Since the change in volume was too large to be accounted for by arteriolar dilatation alone, and there was a simultaneous decrease in pulmonary arterial and left atrial pressures, isoproterenol apparently increased the distensibility of a large but as yet unidentified segment of the pulmonary vascular bed.

Entities:  

Keywords:  BLOOD VOLUME/drug effects; CARDIOTONIC AGENTS/pharmacology; ISOPROTERENOL/pharmacology; RHEUMATIC HEART DISEASE/physiopathology

Mesh:

Substances:

Year:  1963        PMID: 17894029     DOI: 10.1161/01.cir.27.1.77

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  13 in total

1.  THE DIFFUSING CHARACTERISTICS AND PRESSURE-VOLUME RELATIONSHIPS OF THE PULMONARY CAPILLARY BED IN MITRAL VALVE DISEASE.

Authors:  R M MCCREDIE
Journal:  J Clin Invest       Date:  1964-12       Impact factor: 14.808

2.  BEHAVIOR OF NORMAL PULMONARY CIRCULATION DURING CHANGES OF TOTAL BLOOD VOLUME IN MAN.

Authors:  F M DE FREITAS; E Z FARACO; D F DE AZEVEDO; J ZADUCHLIVER; I LEWIN
Journal:  J Clin Invest       Date:  1965-03       Impact factor: 14.808

3.  ["ON LUNG SWELLING AND RIGIDITY": BREATHING MECHANISM STUDIES ON 100 CASES OF MITRAL STENOSIS].

Authors:  J HAMM; P SCHOELMERICH
Journal:  Klin Wochenschr       Date:  1964-11-15

4.  Determinants of pulmonary blood volume.

Authors:  M L Lewis; J Gnoj; V J Fisher; L C Christianson
Journal:  J Clin Invest       Date:  1970-01       Impact factor: 14.808

5.  Hemodynamic effects of isoproterenol on the pulmonary and systemic circulations in dogs.

Authors:  K Turnheim; W Stühlinger; O Kraupp
Journal:  Pflugers Arch       Date:  1971       Impact factor: 3.657

6.  [Cardiac output, heart rate and stroke volume, blood pressure and peripheral circulatory resistance in dogs under the influence of physical work and the administration of catecholamines and atropine].

Authors:  E W Keck
Journal:  Arch Kreislaufforsch       Date:  1965-10

7.  [Clinical rheocardiography].

Authors:  H Heeger
Journal:  Arch Kreislaufforsch       Date:  1970 Sep-Oct

8.  Pulmonary blood volume in mitral stenosis.

Authors:  S B Roy; P Bhardwaj; M L Bhatia
Journal:  Br Med J       Date:  1965-12-18

9.  Estimation of lung volumes from chest radiographs using shape information.

Authors:  R J Pierce; D J Brown; M Holmes; G Cumming; D M Denison
Journal:  Thorax       Date:  1979-12       Impact factor: 9.139

10.  Pulmonary vascular distensibility and lung compliance as modified by dextran infusion and subsequent atropine injection in normal subjects.

Authors:  C Giuntini; A Maseri; R Bianchi
Journal:  J Clin Invest       Date:  1966-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.